Baseline plasma N-terminal pro-B-type natriuretic peptide is associated with the extent of stress-induced myocardial ischemia during dobutamine stress echocardiography

Coronary Artery Disease

Volumn 17, Issue 3, 2006, Pages 255-259

  Feringa, Harm H H ^a   Elhendy, Abdou ^c   Bax, Jeroen J ^b   Boersma, Eric ^a   De Jonge, Robert ^a   Schouten, Olaf ^a   Karagiannis, Stefanos E ^d   Schinkel, Arend F L ^a   Lindemans, Jan ^a   Poldermans, Don ^a,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d ONASSIS CARDIAC SURGERY CENTER   (Greece)

^e NONE   (Netherlands)

Author keywords

Dobutamine stress echocardiography; Myocardial ischemia; Natriuretic peptides; Predictive value

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; UNCLASSIFIED DRUG;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; EXERCISE TEST; FEMALE; HEART MOVEMENT; HEART MUSCLE ISCHEMIA; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; STRESS ECHOCARDIOGRAPHY; UNIVARIATE ANALYSIS;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; ECHOCARDIOGRAPHY, STRESS; FEMALE; HEART RATE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 33748307366     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-200605000-00009     Document Type: Article

References (19)

1. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90:195-203.
2. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87:464-469.
3. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321-328.
4. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. Eur J Heart Fail 2004; 6:257-260.
5. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal probrain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24:1735-1743.
6. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 2004; 110:2168-2174.
7. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al., Australia-New Zealand Heart Failure Group. Plasma N-terminal probrain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001; 37:1781-1787.
8. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal pro-atrial natriuretic peptide. Circulation 1996; 93:1963-1969.
9. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345:1014-1021.
10. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: Results from the AtheroGene Study. Eur Heart J 2005; 26:241-249.
11. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666-675.
12. Poldermans D, Fioretti PM, Boersma E, Bax JJ, Thomson IR, Roelandt JR, et al. Long-term prognostic value of dobutamine-atropine stress echocardiography in 1737 patients with known or suspected coronary artery disease: a single-center experience. Circulation 1999; 99:757-762.
13. Yeo KT, Wu AH, Apple FS, Kroll MH, Christenson RH, Lewandrowski KB, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 2003; 338:107-115.
14. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, et al. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995; 92:1558-1564.
15. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17:1105-1107.
16. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Vogt W, Schomig A, et al. Plasma levels of N-terminal pro-brain natriuretic peptide in patients with coronary artery disease and relation to clinical presentation, angiographic severity, and left ventricular ejection fraction. Am J Cardiol 2005; 95:553-557.
17. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol 2004; 44:1988-1995.
18. Sawada SG, Segar DS, Ryan T, Brown SE, Dohan AM, Williams R, et al. Echocardiographic detection of coronary artery disease during dobutamine infusion. Circulation 1991; 83:1605-1614.
19. Picano E. Stress echocardiography. Expert Rev Cardiovasc Ther 2004; 2:77-88.